References
- Heit JA, Cohen AT, Anderson FA Jr, et al. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood 2005;106:267a. Abstract 910
- Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:338-400S
- MacDougall DA, Feliu AL, Boccuzzi SJ, et al. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health Syst Pharm 2006;63:S5-15
- Caprini JA, Botteman MF, Stephens JM, et al. Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States. Value Health 2003;6:59-74
- Heit JA, O’Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002;162:1245-8
- Ollendorf DA, Vera-Llonch M, Oster G. Cost of venous thromboembolism following major orthopedic surgery in hospitalized patients. Am J Health Syst Pharm 2002;59:1750-4
- White RH, Gettner S, Newman JM, et al. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. N Engl J Med 2000;343:1758-64
- White RH, Romano PS, Zhou H, et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998;158:1525-31
- Edelsberg J, Ollendorf D, Oster G. Venous thromboembolism following major orthopedic surgery: review of epidemiology and economics. Am J Health Syst Pharm 2001;58(Suppl 2):S413
- Costs for hospital discharges with a primary diagnosis of knee or hip replacement. Rockville, MD: U.S. Department of Health & Human Services, 2010. Available at: http://www.hcupnet.ahrq.gov. [Last accessed 29 October 2010]
- Bullano MF, Willey V, Hauch O, et al. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. J Manag Care Pharm 2005;11:663-73
- Saunders ME, Grant RE. Cost effectiveness of low-molecular weight heparin versus warfarin following hip replacement surgery. J Natl Med Assoc 1998;90:677-80
- Colwell CW Jr, Collis DK, Paulson R, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am 1999;81:932-40
- Leclerc JR, Gent M, Hirsh J, et al. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group. Arch Intern Med 1998;158:873-8
- Oster G, Ollendorf DA, Vera-Llonch M, et al. Economic consequences of venous thromboembolism following major orthopedic surgery. Ann Pharmacother 2004;38:377-82
- Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
- Hitos K, Fletcher JP. Venous thromboembolism following primary total hip arthroplasty. Int Angiol 2009;28:215-21
- Samama CM, Ravaud P, Parent F, et al. Epidemiology of venous thromboembolism after lower limb arthroplasty: the FOTO study. J Thromb Haemost 2007;5:2360-7
- Lefebvre P, Vekeman F, Nutescu EA, et al. Risk and costs of bleeding events versus risk and costs of VTE for patients undergoing total hip or total knee arthroplasty. Presented at the 30th Annual Congress of the National Association of Orthopaedic Nurses; May 15–19, 2010; Seattle, WA. Abstract 464
- Vekeman F, Bookhart BK, Lefebvre P, et al. Incidences and associated costs for venous thromboembolism and bleeding events in patients undergoing total hip or total knee arthroplasty. Presented at the Summer Meeting of the American Society of Health System Pharmacists; June 6–9, 2010; Tampa, FL. Abstract 15-T